title: The effects of imatinib on pregnancy outcome.
abstract: Imatinib has now been in use for almost 10 years. Despite this cumulative experience, little is known about its effects on pregnancy; as a result, there are few published data to facilitate the counseling of women who conceive while taking imatinib. The results we now present provide information which may be of use in such circumstances. Of 180 women exposed to imatinib during pregnancy, outcome data are available for 125 (69%). Of those with known outcomes, 50% delivered normal infants and 28% underwent elective terminations, 3 following the identification of abnormalities. There were a total of 12 infants in whom abnormalities were identified, 3 of which had strikingly similar complex malformations that are clearly a cause for concern. It appears that although most pregnancies exposed to imatinib are likely to have a successful outcome, there remains a risk that exposure may result in serious fetal malformations.
authors.affiliation: Department of Haematology, Division of Investigative Science, Imperial College, London, United Kingdom. s.pye@imperial.ac.uk
authors.forename: Seonaid M
authors.initials: SM
authors.lastname: Pye
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
authors.forename: Patricia
authors.initials: P
authors.lastname: Ault
authors.forename: Alan
authors.initials: A
authors.lastname: Hatfield
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Richard
authors.initials: R
authors.lastname: Pilot
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Rosti
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
mesh_terms: D000015:Abnormalities, Multiple / Q000139:chemically induced / Q000453:epidemiology; D000022:Abortion, Spontaneous / Q000139:chemically induced / Q000453:epidemiology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019465:Craniofacial Abnormalities / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000453:epidemiology; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy* / Q000453:epidemiology; D011256:Pregnancy Outcome; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate